20/20 Biolabs Inc 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission File Number: 001-43128 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on whichregistered The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 19, 2026, there were 10,611,528 shares of common stock of the registrant issued and outstanding. 20/20 Biolabs, Inc. Quarterly Report on Form 10-QPeriod Ended March 31, 2026 TABLE OF CONTENTS Item 1.Financial Statements1Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations2Item 3.Quantitative and Qualitative Disclosures About Market Risk9Item 4.Controls and Procedures9 PART IIOTHER INFORMATION Item 1.Legal Proceedings10Item 1A.Risk Factors10Item 2.Unregistered Sales of Equity Securities and Use of Proceeds10Item 3.Defaults Upon Senior Securities10Item 4.Mine Safety Disclosures10Item 5.Other Information10Item 6.Exhibits11 PART IFINANCIAL INFORMATION 20/20 BIOLABS, INC.UNAUDITED CONDENSED FINANCIAL STATEMENTS PageCondensed Balance Sheets as of March 31, 2026 and December 31, 2025 (unaudited)F-1Condensed Statements of Operations for the Three Months Ended March 31, 2026 and 2025 (unaudited)F-2Condensed Statements of Stockholders’ Equity (Deficit) for the Three Months Ended March 31, 2026 and 2025(unaudited)F-3Condensed Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (unaudited)F-5Notes to Unaudited Condensed Financial StatementsF-6 20/20 BIOLABS, INC.CONDENSED BALANCE SHEETS(UNAUDITED) 20/20 BIOLABS, INC.CONDENSED STATEMENTS OF OPERATIONS(UNAUDITED) 20/20 BIOLABS, INC.CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)(UNAUDITED) 20/20 BIOLABS, INC.CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) (CONTINUED)(UNAUDITED) 20/20 BIOLABS, INC.CONDENSED STATEMENTS OF CASH FLOWS(UNAUDITED) 20/20 BIOLABS, INC.NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTSMARCH 31, 2026 NOTE 1—BASIS OF PRESENTATION AND OTHER INFORMATION The accompanying unaudited condensed financial statements of 20/20 Biolabs, Inc. (the “Company”) have been prepared inaccordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial informationand with the instructions to Form 10-Q and Regulation S-X. They do not include all the information and footnotes required by GAAPfor complete financial statements. The March 31, 2026 balance sheet data was derived from audited financial statements but do notinclude all disclosures required by GAAP. The unaudited condensed financial statements should be read in conjunction with thosefinancial statements included in the Company’s Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March31, 2026 (the “Form 10-K”). In the opinion of management, all adjustments considered necessary for a fair presentation of thefinancial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the three months endedMarch 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements as of and for the year end